Application of the CRISPR/Cas9-based gene editing technique in basic research, diagnosis, and therapy of cancer

Abstract

The 2020 Nobel Prize in Chemistry was awarded to Emmanuelle Charpentier and Jennifer Doudna for the development of the Clustered regularly interspaced short palindromic repeats/CRISPR-associated nuclease9 (CRISPR/Cas9) gene editing technology that provided new tools for precise gene editing. It is possible to target any genomic locus virtually using only a complex nuclease protein with short RNA as a site-specific endonuclease. Since cancer is caused by genomic changes in tumor cells, CRISPR/Cas9 can be used in the field of cancer research to edit genomes for exploration of the mechanisms of tumorigenesis and development. In recent years, the CRISPR/Cas9 system has been increasingly used in cancer research and treatment and remarkable results have been achieved. In this review, we introduced the mechanism and development of the CRISPR/Cas9-based gene editing system. Furthermore, we summarized current applications of this technique for basic research, diagnosis and therapy of cancer. Moreover, the potential applications of CRISPR/Cas9 in new emerging hotspots of oncology research were discussed, and the challenges and future directions were highlighted.

Abstract of "Application of the CRISPR/Cas9-based gene editing technique in basic research, diagnosis, and therapy of cancer" by Huimin Zhang, Chunhong Qin, Changming An et al., https://doi.org/10.1186/s12943-021-01431-6, used under its Creative Commons Attribution license (CC-BY); markup removed, otherwise unmodified.